A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx

Archives of Otolaryngology - Head and Neck Surgery

Volumn 122, Issue 8, 1996, Pages 853-857

  Robbins, K Thomas ^a,e   Fontanesi, James ^a   Wong, Frank S H ^a   Vicario, Daniel ^c   Seagren, Stephen ^d   Kumar, Parvesh ^a   Weisman, Robert ^b   Pellitteri, Phillip ^b   Thomas, J Randal ^a   Flick, Pamela ^a   Palmer, Robert ^a   Weir III, Alva ^a   Kerber, Charles ^d   Murry, Thomas ^a   Ferguson, Robert ^a   Los, Gerritt ^b   Orloff, Lisa ^b   Howell, Stephen B ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; SODIUM THIOSULFATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LARYNX CARCINOMA; MALE; MUCOSA INFLAMMATION; PHARYNX CARCINOMA; TREATMENT OUTCOME; VOICE;

EID: 0345791211     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1996.01890200043010     Document Type: Article

References (22)

1. Wolf GT, Hong WK, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: the Department of Veterans Affairs Laryngeal Study Group. N Engl J Med. 1991;324:1685-1690.
2. Demard F, Chauvel P, Santini J, et al. Response to chemotherapy as a justification for modification of the therapeutic strategy for pharyngolaryngeal carcinomas. Head Neck Surg. 1990;12:225-231.
3. Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. Cancer. 1987;60:1178-1183.
4. Pfister DG, Harrison LB, Strong EW, Bosl GJ. Current status of larynx preservation with multimodality therapy. Oncology. 1992;6(3):33-38.
5. Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high dose cisplatin infusion for advanced head and neck malignancies. Head Neck. 1992;14:364-371.
6. Robbins KT, Storniolo AMS, Kerber C, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol. 1994;12(10):2113-2120.
7. Urba S, Forastiere AA, Wolf GT, et al. Intensive continuous infusion high dose cisplatin, 5-fluorouracil and mitoguazone induction chemotherapy for advanced head and neck cancer. Proc Am Soc Clin Oncol. 1989;8:172.
8. Harwood AR, Hawkins NV, Beale FA, et al. Management of advanced glottic cancer: a 10 year review of the Toronto experience. Int J Radiat Oncol Biol Phys. 1979;5:899-904.
9. Peters LJ, Ang KK. The role of altered fractionation in head and neck cancers. Semin Radiat Oncol. 1992;2:180-194.
10. Wendt CD, Peters LJ, Ang K, et al. Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx. Int J Radiat Oncol Biol Phys. 1989;17:1057-1062.
11. Horiot JC. The EORTC radiotherapy group experience: phase III trials in hyperfractionation (HF) and accelerated fractionation (AF) in head and neck cancers. Int J Radiat Oncol Biol Phys. 1991;21(suppl 1):108.
12. Merlano M, Grimaldi A, Benasso M, et al. Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. Am J Clin Oncol. 1988;11:538-542.
13. Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer. 1990;66:1861-1868.
14. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clini-cal experience in patients with solid tumors. J Clin Oncol. 1990;8:911-934.
15. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 1988;48:775-778.
16. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373-4384.
17. Sinclair WK: Hydroxyurea: effects on Chinese hamster cells grown in culture. Cancer Res. 1967;27:297-308.
18. Douple EB, Richmond RC. Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer. 1978;37:98-102.
19. Muggia FM, Glatstein E. Summary of investigations on platinum compounds and radiation reactions. Int J Radiat Oncol Biol Phys. 1979;5:1407-1409.
20. Zak M, Drobnik J. Effects of cis-dichlorodiamineplatinum (II) on the post-irradiation lethality in mice after irradiation with X-rays. Strahlentherapie. 1971; 142:112-115.
21. Eckman WW, Patlak CS, Fenstermacher JD. A critical evaluation of the principles governing the advantages of intra-arterial infusions. J Pharmacokinet Biopharm. 1974;2:257-285.
22. Wheeler RH, Ziessman HA, Medvec BR, et al. Tumor blood flow and systemic shunting in patients receiving intraarterial chemotherapy for head and neck cancer. Cancer Res. 1986;46:4200-4204.